- Home
- TEM vs EXEL Comparison
TEM vs EXEL Comparison
Compare TEM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- EXEL
- Stock Information
- Founded
- TEM 2015
- EXEL 1994
- Country
- TEM United States
- EXEL United States
- Employees
- TEM N/A
- EXEL N/A
- Industry
- TEM
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEM
- EXEL Health Care
- Exchange
- TEM NYSE
- EXEL Nasdaq
- Market Cap
- TEM 9.2B
- EXEL 9.8B
- IPO Year
- TEM 2024
- EXEL 2000
- Fundamental
- Price
- TEM $61.37
- EXEL $36.17
- Analyst Decision
- TEM Buy
- EXEL Buy
- Analyst Count
- TEM 12
- EXEL 18
- Target Price
- TEM $61.60
- EXEL $37.59
- AVG Volume (30 Days)
- TEM 11.3M
- EXEL 2.2M
- Earning Date
- TEM 05-06-2025
- EXEL 05-13-2025
- Dividend Yield
- TEM N/A
- EXEL N/A
- EPS Growth
- TEM N/A
- EXEL 170.77
- EPS
- TEM N/A
- EXEL 1.76
- Revenue
- TEM $803,315,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- TEM $77.53
- EXEL $5.78
- Revenue Next Year
- TEM $24.86
- EXEL $10.94
- P/E Ratio
- TEM N/A
- EXEL $20.64
- Revenue Growth
- TEM 42.93
- EXEL 18.50
- 52 Week Low
- TEM $22.89
- EXEL $20.14
- 52 Week High
- TEM $91.45
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- EXEL 43.89
- Support Level
- TEM N/A
- EXEL $34.90
- Resistance Level
- TEM N/A
- EXEL $40.26
- Average True Range (ATR)
- TEM 0.00
- EXEL 1.21
- MACD
- TEM 0.00
- EXEL -0.19
- Stochastic Oscillator
- TEM 0.00
- EXEL 23.69
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.